Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention
調査の概要
詳細な説明
Overview: Many people recovering from first-episode schizophrenia typically respond very well to their initial course of antipsychotic medications; however, studies indicate that nonadherence rates soar as high as 90% in the first year and do not improve over time. To date, there is no effective psychosocial intervention that improves adherence or reduces the adverse consequences of nonadherence after it occurs. Thus, it is imperative to develop a new intervention to improve medication adherence and improve clinical outcomes in patients recovering from first-episode schizophrenia.
This study is to pilot an intervention specifically suited for patients with first-episode schizophrenia based on the principles of Cognitive Behavioral Therapy (CBT). This is to focus on adherence from the perspective of the patient.
Methods: This study compares the effectiveness of a standard psychoeducation program [Team Solutions (TS)] to a CBT approach known as the Health Dialogue Intervention (HDI). Consenting patients will receive a 4 week stabilization assessment period and then be randomized to a prospective, random-assignment study comparing the effectiveness of TS to HDI to improve medication adherence of patients recovering from first-episode schizophrenia.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- University of Illinois at Chicago
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
There is a 2 step inclusion/exclusion criteria, the first being for assessing overall eligibility to enter the study, and then, for continued outpatient treatment for schizophrenia, schizophreniform disorder, or schizoaffective disorder.
Inclusion criteria for entry into the Evaluation Phase:
- Between 16-45 years of age
- A provisional clinical diagnosis of schizophreniform disorder, schizophrenia, or schizoaffective disorder in last 6 months
- Discharge from inpatient unit for treatment of psychotic symptoms must have occurred in the last 6 months, or, if never hospitalized, initial treatment started in the last 6 months
- Able to fully participate in the informed consent process
- The patient is judged to be an appropriate candidate for ongoing outpatient follow-up at the First-episode Treatment Program at the Psychotic Disorders Program at UIC
Exclusion criteria for the Evaluation Phase:
- Unable to understand informed consent process
- A history of nonresponse to prior antipsychotic trials such that long-term inpatient treatment or clozapine will be recommended
- Prior treatment with clozapine
- Discharge from inpatient treatment for psychotic symptoms, initial treatment, or provisional diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform occurred more than 6 months from enrollment into the evaluation phase
- Pregnancy or stated goal to become pregnant
- Will not be living close enough to the medical center to return for follow-up visits or assessments
- History of geographic instability such that it is judged unlikely that patient will reside in the area
- Currently under arrest for a felony, or an arrest is deemed likely in the near future
- Currently receiving medication over objection by court order
- Currently receiving treatment in another research protocol
Inclusion Criteria for the Treatment Intervention Phase:
- Willingness to transition to receive evaluation and future pharmacologic treatment at the Psychotic Disorders Program at UIC
- Has capacity to understand the risks and benefits of participating in a randomized psychosocial trial
- Willingness to sign informed consent to go into the Treatment Intervention Phase
- Is able to complete a post-test for understanding the nature of the study and what it entails, and the potential risks and benefits of study participation
- Is willing to have therapy sessions recorded for fidelity assessments
- Is willing to receive follow-up independent assessments of adherence status, including separate interviews with trained independent raters, and our contacting the outpatient pharmacy for pharmacy refill records
Exclusion criteria for Treatment Intervention Phase:
- Diagnosis or inpatient treatment for psychotic symptoms occurred more than 6 months from date of enrollment into evaluation phase
- Acutely psychotic individuals may not participate because therapy will not benefit if symptoms are too severe
- Has dropped out of the treatment program and cannot be located for follow-up appointments
- Stated refusal to come for to at least one clinical evaluation appointment at the PDP, or has been a "no show" for at least three consecutive appointments
- Judged to be at significant and imminent risk of harm to self or others*
- Ongoing active substance or alcohol use that is not controlled during the Evaluation Phase, along with refusal of referral to a "dual diagnosis" treatment program for substance abuse problems
- Remains enrolled in another research protocol at UIC*
- Unwilling to consider any additional psychotherapeutic intervention above and beyond coming in to the service for medication management appointment
- Baseline PANSS total score ≥ 90, or has a individual PANSS item of conceptual disorganization (item P2), excitement (P4), or hostility (P7) that is ≥ 5 (moderately severe)*
- Judged to require additional concrete case management services to support medication adherence*
- Receives antipsychotics under coercive conditions (e.g. inpatient or outpatient commitment)*
Note: The exclusion criteria (*) may be present during some parts of the Evaluation Phase and would need to be resolved within the 4 week time period permitted for the Evaluation Phase prior to the Treatment Intervention Phase of study entry.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:CBT
UK-based intervention
|
Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
1. Acceptance of therapeutic intervention as measured by number of sessions attended. 2. Difference in adherence behavior as measured by duration of antipsychotic treatment during follow up (ASV). 3. Differences in adherence attitudes (ROMI).
時間枠:Completion of Study
|
Completion of Study
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
1. Compare the course of symptoms and relapse of patients in HDI to those in the TS.
時間枠:Completion of Study
|
Completion of Study
|
協力者と研究者
捜査官
- 主任研究者:Peter J. Weiden, M.D.、University of Illinois at Chicago
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Cognitive Behavioral Therapyの臨床試験
-
University of MinnesotaNational Institute of Mental Health (NIMH)募集精神病性障害 | 統合失調症 | 統合失調症スペクトラムおよびその他の精神病性障害 | 統合失調感情障害 | 精神病 | 統合失調感情障害 | 統合失調症性障害 | 精神病、感情的 | 精神性気分障害 | 精神病患者番号/その他アメリカ
-
Douglas Mental Health University Institute募集
-
Universitätsklinikum Hamburg-EppendorfCytoSorbents, Inc募集
-
Universitätsklinikum Hamburg-Eppendorf完了